Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

Bree, Kelly; Shan, Yong; Hensley, Patrick J.; Lobo, Niyati; Hu, Chengrui; Tyler, Douglas S.; Chamie, Karim; Kamat, Ashish M.; Williams, Stephen B.

doi:10.1001/jamanetworkopen.2022.3050

Cited by 27 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urine cytology is a non‐invasive test for the diagnosis and follow‐up of patients with BLCA; however, it has a low sensitivity for low‐grade BLCA (LG‐BLCA) 6 . Further studies revealed that the use of urine cytology could not reduce the number of cystoscopies received by patients with BLCA and also highlighted that cystoscopy and cytology are currently overused in low‐risk BLCA patients, increasing the cost of patient care 5,7 . Therefore, developing highly accurate, cost‐effective, rapid and painless methods for diagnosing, classifying and monitoring BLCA are needed.…”

Section: Introductionmentioning

confidence: 99%

Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges

Wang

Jin

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

Bladder cancer (BLCA) is a most common urological tumours with high rate of recurrence, which needs long‐term of follow‐up. To date, diagnosis and surveillance of BLCA still rely on cystoscopy, an invasive and expensive method that increases the difficulty for routine follow‐up. Therefore, exploring new biomarkers or tests is an effective way to improve the current clinical management of BLCA. Recent years, liquid biopsy has received increasing attention, especially for its great potential for clinical application in the non‐invasive detection of tumours. In addition, liquid biopsy involves a wide range of biomarkers, including DNA, RNA, proteins, extracellular vesicles and metabolites in blood, urine or other body fluids. For BLCA, urine is a most ideal body fluid to achieve non‐invasive diagnosis and surveillance. Here, we address recent developments of urine‐based biomarkers or tests for clinical diagnostic challenges in BLCA, such as early detection, minimal residual, recurrence monitoring and therapeutic response. Meanwhile, the many challenges of urine biomarkers that need to be overcome are also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges

Wang

Jin

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

show abstract

“…A publication [ 14 ] analysed a cohort of 13,054 patients with LG Ta NMIBC diagnosed between 1 January 2004–31 December 2014 and to find factors related to treatment costs. The results suggest that cystoscopy was used too frequently.…”

Section: Introduction: Bladder Cancer Issues and Urinary Biomarkersmentioning

confidence: 99%

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Matuszczak

Kiljańczyk

Salagierski

2022

IJMS

View full text Add to dashboard Cite

The non-muscle invasive bladder cancer tends to recur and progress. Therefore, it requires frequent follow-ups, generating costs and making it one of the most expensive neoplasms. Considering the expensive and invasive character of the current gold-standard diagnostic procedure, white-light cystoscopy, efforts to find an alternative method are ongoing. Although the last decade has seen significant advancements in urinary biomarker tests (UBTs) for bladder cancer, international guidelines have not recommended them. Currently, the paramount urgency is to find and validate the test with the best specificity and sensitivity, which would allow for the optimizing of diagnosis, prognosis, and a treatment plan. This review aims to summarise the up-to-date state of knowledge relating to UBTs and new developments in the detection, prognosis, and surveillance of bladder cancer and their potential applications in clinical practice.

show abstract

“…The standard treatment for NMIBC has been transurethral resection of the bladder tumor (TURBT), with or without adjuvant intravesical instillation (IVI) of chemotherapy or bacillus Calmette-Gueŕin (BCG) therapy (3,4). However, 40%-80% of initially treated NMIBC patients experience tumor recurrence, and approximately 15% eventually progress to MIBC (5)(6)(7). The risk-scoring models developed by the European Organisation for Research and Treatment of Cancer (EORTC) (3) and the Spanish Urological Organization (Club Urologico Español de Tratamiento Oncologico, CUETO) (4) have been widely used to predict the survival and prognosis of patients with NMIBC (8,9).…”

Section: Introductionmentioning

confidence: 99%

Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundTransurethral resection of the bladder tumor with or without adjuvant intravesical instillation (IVI) has been the standard treatment for non-muscle-invasive bladder cancer (NMIBC), whereas a high percentage of patients still experience local tumor recurrence and disease progression after receiving the standard treatment modalities. Unfortunately, current relevant prediction models for determining the recurrent and progression risk of NMIBC patients are far from impeccable.MethodsClinicopathological characteristics and follow-up information were retrospectively collected from two tertiary medical centers between October 2018 and June 2021. The least absolute shrinkage and selection operator (LASSO) and Cox regression analysis were used to screen potential risk factors affecting recurrence-free survival (RFS) of patients. A nomogram model was established, and the patients were risk-stratified based on the model scores. Both internal and external validation were performed by sampling the model with 1,000 bootstrap resamples.ResultsThe study included 299 patient data obtained from the Affiliated Hospital of Xuzhou Medical University and 117 patient data obtained from the First Affiliated Hospital of Guangxi Medical University. Univariate regression analysis suggested that urine red blood cell count and different tumor invasion locations might be potential predictors of RFS. LASSO-Cox regression confirmed that prior recurrence status, times of IVI, and systemic immune-inflammation index (SII) were independent factors for predicting RFS. The area under the curve for predicting 1-, 2-, and 3-year RFS was 0.835, 0.833, and 0.871, respectively. Based on the risk stratification, patients at high risk of recurrence and progression could be accurately identified. A user-friendly risk calculator based on the model is deposited at https://dl0710.shinyapps.io/nmibc_rfs/.ConclusionInternal and external validation analyses showed that our model had excellent predictive discriminatory ability and stability. The risk calculator can be used for individualized assessment of survival risk in NMIBC patients and can assist in guiding clinical decision-making.

show abstract

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

Cited by 27 publications

References 46 publications

Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges

Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer

Contact Info

Product

Resources

About